A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Clinical trial NCT04730349 · TERMINATED

Trial details

NCT number: NCT04730349
Sponsor: Bristol-Myers Squibb
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ependymoma Ewing Sarcoma High-grade Glioma Leukemia and Lymphoma Medulloblastoma Miscellaneous Brain Tumors Miscellaneous Solid Tumors Neuroblastoma Relapsed, Refractory Malignant Neoplasms Rhabdomyosarcoma

Start date: 2021-06-03
Primary completion: 2022-06-22
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.